Search

everythinglearnresearchcommunity

for

Search:↓

Vitamin D supplementation may have led to slight hair regrowth and density improvement. Other treatments discussed include finasteride, minoxidil, and maintaining optimal vitamin D levels.

In Austria, finasteride prescriptions are restricted due to suicide risk concerns, with new prescriptions only for current users. Alternatives like topical finasteride, dutasteride, and online purchases face legal challenges.

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

Finasteride users cannot donate blood due to potential risks to pregnant women, requiring a one-month cessation before donating. Dutasteride requires a six-month deferral, and topical applications are not restricted.

PP405 is expected to be available in 2028, with ongoing discussions about its timeline and potential effectiveness. Current treatments mentioned include sublingual Minoxidil and Vederamicd, with some users experiencing side effects from oral Minoxidil.

A user shared their 9-year experience using oral Minoxidil and Dutasteride for hair loss, noting initial side effects like dizziness and shedding but achieving stable results. They emphasized the importance of confidence over appearance and mentioned that the treatment has been worth it for them.

Ketoconazole shampoo does not significantly reduce systemic or scalp DHT levels and is mainly used for its anti-fungal and anti-inflammatory effects. It is not a replacement for finasteride, which is recommended by some users despite concerns about side effects.

A user needs to stop finasteride for 7 days to donate blood due to haemochromatosis. They are concerned if this break will affect their hair loss progress after 6 weeks of use.

A user successfully regrew their hair over 8 months using topical minoxidil, finasteride, a healthy lifestyle, and derma stamping. They emphasize the results are genuine and not from hair transplants.

The user noticed thicker hair and reduced dandruff after using Nizoral 2% (ketoconazole) every few days, alongside topical minoxidil 5% for over a year. They plan to reduce Nizoral use to once a week to avoid scalp irritation.

A 44-year-old man experienced significant hair regrowth after switching from topical to 1.25mg oral minoxidil and 0.5mg daily finasteride, with no side effects. He noticed hair thickening after two months and credits the oral form's effectiveness.

Finasteride does not significantly affect muscle gains and can slightly increase testosterone levels. Creatine is generally considered safe to use with finasteride, though some believe it may increase DHT levels, potentially affecting hair loss.

Stemoxydine is more expensive than minoxidil and finasteride, costing $50-$150 per month. The discussion questions why the cost is higher despite efficacy.

A user shared their 2+ years progress on Oral Dutasteride and Sublingual Minoxidil for hair loss. Another user asked about the form of Minoxidil used sublingually.

A user shared their experience of getting 1400 hair grafts 5 months post-op with Dr. Vikram Jayaprakash, mentioning they have been using finasteride for 2.5 years. The responses include compliments on the results and questions about the cost and current treatments.

The conversation is about a 27-year-old male using 1mg of finasteride and 5mg of minoxidil daily for hair loss, noticing slow improvement. He is unsure if using a dermaroller will help while on oral minoxidil.

A user is seeking a titanium dioxide-free finasteride pill due to health concerns. They have not found a suitable supplier yet.

A user shared their experience with hair loss treatments, including finasteride, minoxidil, and RU58841, which improved their hair from a diffuse NW3 to a solid NW2 - 2.5. They noticed significant changes in how people treated them after regrowing their hair, suggesting that attractiveness can greatly impact social interactions and opportunities.

The post discusses the user's experience with hair loss treatment using finasteride, clobetasol propionate, and ketoconazole shampoo. The conversation warns about the potential side effects of clobetasol, a powerful topical steroid, and emphasizes its short-term usage.

User asks if Kintor, HMI-115, or Olix will release hair loss drugs in 2023. Conversation discusses potential treatments and release dates.

User shared 15-month progress using Oral Dutasteride and Sublingual Minoxidil for hair loss. Treatment improved hair density, now considering hair transplant with fewer grafts.

User shares 1-month vs 9-month finasteride results for hair loss. Commenters discuss photo angles, hair regrowth, and side effects.

Treatments for hair loss, specifically the use of minoxidil, finasteride and RU58841. Replies to this post suggest that users should share relevant information publicly rather than through direct messages.

Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.

Hair loss and potential treatments, primarily focusing on Finasteride and Minoxidil. Other solutions discussed include PRP, dermarolling, LLP, and scalp tension relief.

HMI-115, a potential treatment for hair loss that can reverse miniaturization and make individual hairs thicker, as evidenced by data from macaques given the treatment and one subject in the phase I trial.

A hair tattoo substitute for a hair transplant, which many people felt was not a good idea. Several treatments were suggested as alternatives, such as Scalp Micro Pigmentation (SMP) and wigs.

A user's experience with hair loss and their current regimen of RU58841, Dutasteride 0.5mg, Minoxidil 2.5mg, and Finasteride 1mg to attempt regrowth.

A clinical trial for hair loss treatments involving Minoxidil, Finasteride, and RU58841, and when the results of the trial will be available.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.